Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity
Executive Summary
The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25
You may also be interested in...
Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug
Alzheimer’s Imaging Agents Should Be Validated With Autopsies, Panel Says
Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded
Alzheimer’s Biomarker Data Ready For Release; Analyses Pose Next Challenge
Biomarker data for Alzheimer's disease will be publicized early this year, one of a number of government and private efforts aimed at pushing research forward in 2008